{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:10:10Z","timestamp":1788775810571,"version":"build-2803163510"},"reference-count":41,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013699","name":"The Ohio State University Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["CC13712-PG101183-AS108825"],"award-info":[{"award-number":["CC13712-PG101183-AS108825"]}],"id":[{"id":"10.13039\/100013699","id-type":"DOI","asserted-by":"publisher"}]},{"award":["CC13712-PG101183-AS108825"],"award-info":[{"award-number":["CC13712-PG101183-AS108825"]}],"id":[{"id":"https:\/\/ror.org\/028t46f04","id-type":"ROR","asserted-by":"publisher"}]},{"name":"The Ohio State University College of Medicine","award":["CC14174-PG107832-AS108825"],"award-info":[{"award-number":["CC14174-PG107832-AS108825"]}]},{"award":["CC14174-PG107832-AS108825"],"award-info":[{"award-number":["CC14174-PG107832-AS108825"]}],"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"Paul Calabresi Career Development Award for Clinical Oncology","doi-asserted-by":"publisher","award":["K12CA133250"],"award-info":[{"award-number":["K12CA133250"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Sarcomatoid renal cell carcinoma (sRCC) is an aggressive RCC subtype with a poor prognosis. Although racial disparities in RCC outcomes are reported, survival patterns across racial and ethnic groups in metastatic sRCC (msRCC) remain unclear. Methods: We conducted a retrospective analysis of 2122 patients with msRCC diagnosed between 2010 and 2020 using the Surveillance, Epidemiology, and End Results (SEER) database. Patients were categorized by race and ethnicity as non-Hispanic White, non-Hispanic Black, Hispanic, Asian\/Pacific Islander, or American Indian\/Alaska Native. Three-year cancer-specific survival (CSS) and overall survival (OS) were estimated using Kaplan\u2013Meier methods. Multivariable Cox proportional hazards regression models were used to evaluate racial disparities in survival. Results: Non-Hispanic Black patients experienced the poorest outcomes, with 3-year CSS and OS of 9.3% and 8.6%, compared with 23.3% and 20.9% in non-Hispanic White, 22.1% and 19.0% in Hispanic, 21.2% and 19.4% in Asian\/Pacific Islander, and 23.4% and 20.7% in American Indian\/Alaska Native patients. Non-Hispanic Black patients were associated with higher estimated hazards of cancer-specific mortality (HR = 1.5, p &lt; 0.0001) and overall mortality (HR = 1.5, p &lt; 0.0001) versus non-Hispanic White. From 2010\u20132015 to 2016\u20132020, survival improved across most racial groups with the introduction of immune checkpoint inhibitors. However, non-Hispanic Black patients remained the only group with persistently inferior survival. Subgroup analysis further demonstrated worse survival for non-Hispanic Black patients in both clear cell msRCC and non-clear cell msRCC subgroups. Conclusions: Although survival was higher during the later diagnosis period, non-Hispanic Black patients with msRCC continued to have the poorest observed survival. These differences may be associated with unmeasured social, structural, socioeconomic, healthcare access, treatment, or clinical factors, but their causes cannot be determined from this observational study. Further research is needed to identify the factors underlying these survival differences.<\/jats:p>","DOI":"10.3390\/cancers18172884","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:23:37Z","timestamp":1788773017000},"page":"2884","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial Disparities in Survival Outcomes for Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A SEER-Based Retrospective Analysis (2010\u20132020)"],"prefix":"10.3390","volume":"18","author":[{"given":"Lingbin","family":"Meng","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4461-9637","authenticated-orcid":false,"given":"Xiaowei","family":"Malone","sequence":"additional","affiliation":[{"name":"AdventHealth, Tampa, FL 33613, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-4154","authenticated-orcid":false,"given":"Changchuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9922-9627","authenticated-orcid":false,"given":"Xuefeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3759-2148","authenticated-orcid":false,"given":"Qi-En","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Feng","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Akshay","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Urology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6166-2807","authenticated-orcid":false,"given":"Shang-Jui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Qingqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Shihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6108-3378","authenticated-orcid":false,"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"ref_1","first-page":"100640","article-title":"The Significance of Sarcomatoid and Rhabdoid Dedifferentiation in Renal Cell Carcinoma","volume":"33","author":"Hahn","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid Renal Cell Carcinoma: Biology, Natural History and Management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e23153","DOI":"10.1200\/JCO.2024.42.16_suppl.e23153","article-title":"Racial Disparities in Incidence and Survival in Renal Cell Carcinoma in Adolescents and Young Adults (AYA)","volume":"42","author":"Wasifuddin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ikuemonisan, J., Aremu, T.O., Oyejinmi, I., Ajala, C., Anikpezie, N., Akinso, O., Mtengwa, M., David, A., Olokede, O., and Adejoro, O. (2023). Racial Disparities in Nephrectomy and Mortality among Patients with Renal Cell Carcinoma: Findings from SEER. PLoS Glob. Public Health, 3.","DOI":"10.1371\/journal.pgph.0001314"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102327","DOI":"10.1016\/j.clgc.2025.102327","article-title":"Racial Differences in Survival for Locally Advanced Renal Cell Carcinoma","volume":"23","author":"Kanumuambidi","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2430975","DOI":"10.1001\/jamanetworkopen.2024.30975","article-title":"Racial Disparities in Cancer Stage at Diagnosis and Survival for Adolescents and Young Adults","volume":"7","author":"Taparra","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Anastos, H., Martini, A., Waingankar, N., Paulucci, D.J., Beksac, A.T., Daza, J., Patel, H.V., Gin, G.E., Sfakianos, J.P., and Badani, K.K. (2020). Black Race May Be Associated with Worse Overall Survival in Renal Cell Carcinoma Patients. Urol. Oncol. Semin. Orig. Investig., 38.","DOI":"10.1016\/j.urolonc.2020.08.034"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO.2006.10.0156","article-title":"Disparities in Treatment and Outcome for Renal Cell Cancer among Older Black and White Patients","volume":"25","author":"Berndt","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a Multicenter, Phase 2 Study of Nivolumab and Ipilimumab for Patients with Advanced Rare Genitourinary Malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2171672","DOI":"10.1080\/21645515.2023.2171672","article-title":"Immune Checkpoint Inhibitors in Non-Conventional Histologies of Renal-Cell Carcinoma","volume":"19","author":"Bersanelli","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MOU.0000000000000940","article-title":"Immunotherapy-Based Combinations in the First-Line Treatment of Metastatic Renal Cell Carcinoma with Sarcomatoid Features: A Systematic Review and Network Meta-Analysis","volume":"32","author":"Quhal","year":"2022","journal-title":"Curr. Opin. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euros.2024.10.002","article-title":"Trends and Outcomes in Sarcomatoid Renal Cell Carcinoma: Analysis of the National Cancer Data Base","volume":"71","author":"Wang","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.juro.2008.09.009","article-title":"Histopathological Characteristics of Localized Renal Cell Carcinoma Correlate with Tumor Size: A SEER Analysis","volume":"181","author":"Rothman","year":"2009","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.urology.2021.08.070","article-title":"Disparities in the Treatment and Survival of Metastatic Renal Cell Carcinoma","volume":"165","author":"Metcalf","year":"2022","journal-title":"Urology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cncr.27690","article-title":"Racial Disparity in Renal Cell Carcinoma Patient Survival According to Demographic and Clinical Characteristics","volume":"119","author":"Chow","year":"2013","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Alam, R., Rezaee, M.E., Pallauf, M., Elias, R., Yerrapragada, A., Enikeev, D., Fang, D., Shariat, S.F., Woldu, S.L., and Ged, Y.M.A. (2023). Socioeconomic Determinants of Racial Disparities in Survival Outcomes among Patients with Renal Cell Carcinoma. Urol. Oncol., 41.","DOI":"10.1016\/j.urolonc.2023.08.016"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cam4.578","article-title":"Racial Disparities in Overall Survival among Renal Cell Carcinoma Patients with Young Age and Small Tumors","volume":"5","author":"Schwartz","year":"2016","journal-title":"Cancer Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102639","DOI":"10.1016\/j.canep.2024.102639","article-title":"Changes in the Overall Survival of Patients with Metastatic Renal Cell Carcinoma in the Era of Immune-Checkpoint Inhibitors","volume":"92","author":"Adhikari","year":"2024","journal-title":"Cancer Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1587365","DOI":"10.1155\/2022\/1587365","article-title":"Survival Improvement in Patients with Renal Cell Carcinoma and Disparities between Different Sexes, Races, and Socioeconomic Status: 1977-2016","volume":"2022","author":"Ouyang","year":"2022","journal-title":"J. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.clgc.2020.12.010","article-title":"Racial Diversity Among Histology of Renal Cell Carcinoma at an Urban Medical Center","volume":"19","author":"Wong","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_21","first-page":"100639","article-title":"Advanced Papillary Renal Cell Carcinoma: Epidemiology, Genomic Drivers, Current Therapies, and Ongoing Trials","volume":"33","author":"Sweeney","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_22","first-page":"24","article-title":"Rate of Renal Cell Carcinoma Subtypes in Different Races","volume":"37","author":"Sankin","year":"2011","journal-title":"Int. Braz. J. Urol. Off. J. Braz. Soc. Urol."},{"key":"ref_23","first-page":"202","article-title":"Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population","volume":"32","author":"Lichtensztajn","year":"2023","journal-title":"Cancer Epidemiol. Biomark. Prev. A Publ. Am. Assoc. Cancer Res. Cosponsored BY Am. Soc. Prev. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.urology.2006.02.036","article-title":"Racial Disparity in Outcomes of a Clinical Trial Population with Metastatic Renal Cell Carcinoma","volume":"68","author":"Tripathi","year":"2006","journal-title":"Urology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/oncolo\/oyad173","article-title":"Racial Disparities in MiT Family Translocation Renal Cell Carcinoma","volume":"28","author":"Lu","year":"2023","journal-title":"Oncologist"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lei, B., and Saxena, A. (2023). Abstract C049: Investigating Cancer Racial Disparities through TCGA Transcriptomic and Proteomic Database. Cancer Epidemiol. Biomark. Prev., 32.","DOI":"10.1158\/1538-7755.DISP22-C049"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JCO.2025.43.5_suppl.442","article-title":"Racial Disparities in Renal Cell Carcinoma Histology and Outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191)","volume":"43","author":"Lu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/cncr.30146","article-title":"Racial Disparities in Survival among Patients with Advanced Renal Cell Carcinoma in the Targeted Therapy Era","volume":"122","author":"Rose","year":"2016","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102104","DOI":"10.1016\/j.clgc.2024.102104","article-title":"Racial and Ethnic Disparities in Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy","volume":"22","author":"Gupta","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Olsen, T.A., Martini, D.J., Goyal, S., Liu, Y., Evans, S.T., Magod, B., Brown, J.T., Yantorni, L., Russler, G.A., and Caulfield, S. (2021). Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.701345"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e251201","DOI":"10.1001\/jamanetworkopen.2025.1201","article-title":"Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US","volume":"8","author":"Ozay","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2020.06.021","article-title":"Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial","volume":"79","author":"Rini","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100101","DOI":"10.1016\/j.esmoop.2021.100101","article-title":"Efficacy and Correlative Analyses of Avelumab plus Axitinib versus Sunitinib in Sarcomatoid Renal Cell Carcinoma: Post Hoc Analysis of a Randomized Clinical Trial","volume":"6","author":"Choueiri","year":"2021","journal-title":"ESMO Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.18632\/oncotarget.14122","article-title":"Genomic Differences between Black and White Patients Implicate a Distinct Immune Response to Papillary Renal Cell Carcinoma","volume":"8","author":"Paulucci","year":"2017","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e185963","DOI":"10.1172\/jci.insight.185963","article-title":"Circulating Immune Biomarkers Correlating with Response in Patients with Metastatic Renal Cell Carcinoma on Immunotherapy","volume":"10","author":"Hwang","year":"2025","journal-title":"JCI Insight"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chen, X., Meng, F., and Jiang, R. (2021). Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.746976"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17588359251316243","DOI":"10.1177\/17588359251316243","article-title":"Association of Baseline Inflammatory Biomarkers and Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors","volume":"17","author":"Yildirim","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.urology.2020.10.055","article-title":"The Association Between Race and 5-Year Survival in Patients With Clear Cell Renal Cell Carcinoma: A Cohort Study","volume":"148","author":"Jivanji","year":"2021","journal-title":"Urology"},{"key":"ref_40","first-page":"263","article-title":"Racial and Ethnic Differences in Survival in Contemporary Metastatic Renal Cell Carcinoma Patients, According to Alternative Treatment Modalities","volume":"31","author":"Luzzago","year":"2020","journal-title":"Cancer Causes Control"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.canep.2018.04.006","article-title":"Effect of African-American Race on Cancer Specific Mortality Differs According to Clear Cell vs. Non-Clear Cell Histologic Subtype in Metastatic Renal Cell Carcinoma","volume":"54","author":"Marchioni","year":"2018","journal-title":"Cancer Epidemiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2884\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:38:20Z","timestamp":1788773900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":41,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172884"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172884","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]}}}